PDAC
Peridot Acquisition Corp.
Set alert
11.23 0.00 0.00%
10.42 Day range 11.58
52-week range unavailable
- Open
- 11.02
- Prev close
- 11.23
- Mkt cap
- 421.12M
- Vol
- 582.67K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.42
- High
- 11.58
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 4.19
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.90
- 200-d avg
- 11.15
- 1y target
- 0.00
Key statistics
- Market cap
- 421.12M
- Enterprise value
- 392.62M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 84.44
- EPS (TTM)
- -0.031
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 563
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 30.00M
- Short % of float
- 5.51%
- 50-day average
- 10.90
- 200-day average
- 11.15
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About Peridot Acquisition Corp.
As of August 10, 2021, Peridot Acquisition Corp. was acquired by Li-Cycle Corp, in a reverse merger transaction. Peridot Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, recapitalization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Houston, Texas.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- peridotspac.com
News
- Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
- Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
- Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
- Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
- Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
- Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
- Manganese X Energy Shares PDAC 2026 Interview Featuring CEO Martin Kepman
- Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway
- Revolution Medicines (RVMD) Hits All-Time Highs After Groundbreaking Cancer Trial Results
Your note
Sign in to keep a note on PDAC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS O'Connor LLC | 7.08% | 2,123,430 | 22.61M | Mar 30, 2021 |
| Arena Capital Advisors, LLC- CA | 6.45% | 1,935,905 | 20.62M | Mar 30, 2021 |
| Falcon Edge Capital, LP | 4.34% | 1,302,433 | 13.87M | Mar 30, 2021 |
| Millennium Management LLC | 4.18% | 1,254,467 | 13.36M | Mar 30, 2021 |
| Arosa Capital Management LP | 3.61% | 1,082,500 | 11.53M | Mar 30, 2021 |
| SIR Capital Management, L.P. | 3.06% | 916,530 | 9.76M | Mar 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco Small Cap Value Fd | 0.52% | 156,815 | 1.61M | Apr 29, 2021 |
| Collaborative Inv Ser Tr-SPAC and New Issue ETF | 0.50% | 150,985 | 1.61M | Mar 30, 2021 |
| BNY-Mellon Small Cap Multi Strategy Fund | 0.44% | 132,589 | 1.34M | May 30, 2021 |
| Principal Diversified Real Asset Fd | 0.36% | 106,615 | 1.07M | May 30, 2021 |
| BlackRock Global Impact Fund | 0.14% | 43,265 | 443.03K | Apr 29, 2021 |
| Primecap Odyssey Aggressive Growth Fund | 0.12% | 36,800 | 448.22K | Jun 29, 2021 |